Table 2.

Drug–Drug Interactions Between DAAs and ARTs^10,13-22

	Tenofovir	Efavirenz	Rilpivirine	Etravirine	Darunavir/r	Atazanavir/r	Lopinavir/r	Fosamprenavir/r	Ritonavir	INSTIa	Maraviroc
Sofosbuvir	√	√	√	√	√	√	√	√	√	√	√
Simeprevir	√	X	√	X	X	X	X	X	X	√	√
Telaprevir	√	↑	√	√	X	√	X	X	±	√	↕
Boceprevir	√	X	√	X	X	X	X	X	X	√	↕
Daclatasvir	√	↑	√	---	↓	↓	↓	↓	↓	√	√
Ledipasvir	√b	√	√	---	Xb	Xb	Xb	X	Xb	√	---
Grazoprevir	√	---	---	---	X	X	X	X	X	√	---
Elbasvir	√	X	---	---	X	X	X	X	X	√	---
3Dc	√	X	X	---	---	√	X	---	±	√	---

√, Co-administered without dose adjustment; X, cannot be co-administered; ↑, need to increase DAA dosage when co-administered; ↓, need to decrease DAA dosage when co-administered; ↕, need to decrease maraviroc dosage when co-administered; dashed bar, no data available; ±, varies based on protease inhibitor.

^aINSTI, integrase inhibitor, not including cobicistat/elvitegravir.

^bLedipasvir can increase tenofovir levels, boosted PIs with tenfovir is not recommended.

^cCombination of paritaprevir/r-ombitasvir and dasabuvir.